On December 30 2020 the Oxford-AstraZeneca vaccine was approved for use in the UK. There will be more than 500,000 doses available and the vaccine is easier to store and distribute than the Pfizer-BioNTech vaccine. This will, no doubt, have an impact on the share price of the company. Investors are likely to buy shares with the hope that the share price of AstraZeneca will rise following this news and the hope that the vaccine will be approved for use in other countries worldwide.
|52-week range||6736p - 10116.2528p|
|50-day moving average||7251.278p|
|200-day moving average||7594.2607p|
|Wall St. target price||78.83p|
|Dividend yield||2.8p (3.72%)|
|Earnings per share (TTM)||175.7p|
Share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
|Platform||Platform fee||Min. initial deposit||Trading fee estimate|
|Capital at risk|
|Capital at risk|
|Capital at risk|
|£9.99 per month||No minimum||£7.99
|Capital at risk|
|Capital at risk|
|£36 per year||£20||£9.50
|Capital at risk|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|3 months (2021-02-12)||3.27%|
|6 months (2020-11-13)||-10.63%|
|1 year (2020-05-14)||-11.98%|
|2 years (2019-05-14)||32.95%|
|3 years (2018-05-14)||45.70%|
|5 years (2016-05-13)||95.81%|
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.
AstraZeneca's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 43x. In other words, AstraZeneca shares trade at around 43x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, AstraZeneca's P/E ratio is best considered in relation to those of others within the drug manufacturers-general industry or those of similar companies.
AstraZeneca's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3398. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AstraZeneca's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider AstraZeneca's PEG ratio in relation to those of similar companies.
AstraZeneca's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping £6.8 billion.
The EBITDA is a measure of a AstraZeneca's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
|Revenue TTM||£26.6 billion|
|Operating margin TTM||15.58%|
|Gross profit TTM||£21.4 billion|
|Return on assets TTM||4.05%|
|Return on equity TTM||20.8%|
|Market capitalisation||£100.1 billion|
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like AstraZeneca.
AstraZeneca's total ESG risk: 28.52
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and AstraZeneca's overall score of 28.52 (as at 12/31/2018) is nothing to write home about – landing it in it in the 45th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like AstraZeneca is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
To gain some more context, you can compare AstraZeneca's total ESG risk score against those of similar companies.
AstraZeneca's environmental score: 0.19/100
AstraZeneca's environmental score of 0.19 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that AstraZeneca is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
AstraZeneca's social score: 15.45/100
AstraZeneca's social score of 15.45 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that AstraZeneca is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
AstraZeneca's governance score: 8.88/100
AstraZeneca's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that AstraZeneca is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
AstraZeneca's controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, AstraZeneca scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that AstraZeneca hasn't always managed to keep its nose clean.
Wondering how that compares? Below are the controversy scores of similar companies.
|Total ESG score||28.52|
|Total ESG percentile||44.72|
|Environmental score percentile||3|
|Social score percentile||3|
|Governance score percentile||3|
|Level of controversy||3|
Dividend payout ratio: 66.35% of net profits
Recently AstraZeneca has paid out, on average, around 66.35% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.75% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 2.75% return on their shares, in the form of dividend payments. In AstraZeneca's case, that would currently equate to about 2.8p per share.
AstraZeneca's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 24 February 2021 (the "ex-dividend date").
AstraZeneca's dividend payout ratio is perhaps best considered in relation to those of similar companies.
Over the last 12 months, AstraZeneca's shares have ranged in value from as little as 6736p up to 10116.2528p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while AstraZeneca's is 0.1932. This would suggest that AstraZeneca's shares are less volatile than average (for this exchange).
To put AstraZeneca's beta into context you can compare it against those of similar companies.
Ever wondered how to buy shares in CarGurus? We explain how and compare a range of providers that can give you access to many brands, including CarGurus.
Ever wondered how to buy shares in SemiLEDs? We explain how and compare a range of providers that can give you access to many brands, including SemiLEDs.
Everything we know about the TikTok IPO, plus information on how to buy it.
Everything we know about the Robinhood IPO, plus information on how to buy it.
Ever wondered how to buy shares in Lexaria Bioscience? We explain how and compare a range of providers that can give you access to many brands, including Lexaria Bioscience.
Ever wondered how to buy shares in Stealth BioTherapeutics? We explain how and compare a range of providers that can give you access to many brands, including Stealth BioTherapeutics.
Ever wondered how to buy shares in iBio? We explain how and compare a range of providers that can give you access to many brands, including iBio.
Everything we know about the Endeavor Group IPO, plus information on how to buy it.
Ever wondered how to buy shares in Farmmi? We explain how and compare a range of providers that can give you access to many brands, including Farmmi.
Ever wondered how to buy shares in Pure Cycle? We explain how and compare a range of providers that can give you access to many brands, including Pure Cycle.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.